1. Home
  2. Directory
  3. Illinois
  4. Burr Ridge
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1720140270

EDWIN POSADAS MD
Prescription History 1720140270
Internal Medicine - Hematology & Oncology in Burr Ridge, IL


Quality Rating: 87.67 out of 100 score

NPI Status: Active since December 14, 2006

Contact Information

180 HARVESTER DR STE 110
BURR RIDGE, IL
ZIP 60527
Phone: (773) 834-4064

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for EDWIN POSADAS MD, an active Hematology & Oncology specialist practicing in Burr Ridge, IL. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 125 documented patient claims. Among these therapy options, the most frequently utilized medication is Orgovyx, which accounts for 70 claims alone.

Medication Index

E
N
O
No matching medications currently found on file.

Erleada

Generic Formulation: ApalutamideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
IL State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills29.3
Peer Average Days Supply878
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 57.1% less volume than the regional standard for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $180,747.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,062.27

State Avg Cost Per Claim

$14,906.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apalutamide is used to treat men with prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Nubeqa

Generic Formulation: DarolutamideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 43
30-Day Fills 43.0
Days Supply 1,290
IL State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills26.0
Peer Average Days Supply778
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 72.0% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $549,279.70 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,773.95

State Avg Cost Per Claim

$13,062.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Darolutamide is used to treat a certain type of prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Orgovyx

Generic Formulation: RelugolixSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 70
30-Day Fills 70.0
Days Supply 2,100
IL State Average Benchmarks
Peer Average Claims57.0
Peer Average 30-Day Fills57.9
Peer Average Days Supply1,727
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $188,932.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,699.04

State Avg Cost Per Claim

$2,605.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Relugolix is used to treat prostate cancer in men. It is not a cure. Most types of prostate cancer need the male hormone testosterone to grow and spread. Relugolix works by reducing the amount of testosterone that the body makes. This helps slow or stop the growth of cancer cells.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like EDWIN POSADAS MD provides transparency into local medical care patterns within Burr Ridge, IL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.